Company / Operating Income
Jade Biosciences, Inc. Operating Income History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$74.6M
FY2024
5-year range
-$81.4M / -$8.9M
FY2020-FY2024
Trend
+8.4%
vs FY2023
Sector context
#81 of 202
Health Care
What the data says
At -$75M, Jade Biosciences, Inc.'s operating income ranks #81 of 202 in the Health Care sector. Operating Income returned to growth in FY2024 after 3 years of decline, reaching -$75M.
Based on SEC 10-K filings.
-$75M in FY2024.
Declined from -$53M to -$75M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#81 of 202 in Health CareTop 40% of 202This company -$74.6M Sector average $70.7M
▼
-205.5% below sector average
Key checks
Key Insights
- In FY2024, operating income increased 8.4% year-over-year.
- Ranks #81 out of 202 companies in the Health Care sector.
- Peak operating income was recorded in FY2020.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$74.6M | +8.4% |
| FY2023 | -$81.4M | -52.9% |
| FY2022 | -$53.2M | -131.2% |
| FY2021 | -$23.0M | -159.0% |
| FY2020 | -$8.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026